Autolus Therapeutics plc Financing Cash Flow
Autolus Therapeutics plc (AUTL) reported Financing Cash Flow of -$4.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Autolus Therapeutics plc net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$2.14M.
- Autolus Therapeutics plc net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$2.06M.
- Autolus Therapeutics plc net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$1.80M, a 105.99% decline year-over-year.
- Autolus Therapeutics plc net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$1.77M, a 1058.92% decline year-over-year.
- Autolus Therapeutics plc net cash provided by (used in) financing activities for fiscal 2025 was -$4.34M, a 100.74% decline from fiscal 2024.
- Autolus Therapeutics plc net cash provided by (used in) financing activities for fiscal 2024 was $589.55M.
- Autolus Therapeutics plc net cash provided by (used in) financing activities for fiscal 2023 was -$883.00K, a 100.39% decline from fiscal 2022.
- Autolus Therapeutics plc net cash provided by (used in) financing activities for fiscal 2022 was $223.61M, a 21.28% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.20M 10-Q · filed 2026-08-11 | -$6.00M derived: sum of 3 quarters · filed 2026-08-11 | -$7.77M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$2.06M 10-Q · filed 2026-05-14 | -$3.86M derived: sum of 2 quarters · filed 2026-05-14 | -$5.63M derived: sum of 3 quarters · filed 2026-05-14 | -$6.40M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$3.57M derived: sum of 2 quarters · filed 2026-03-27 | -$4.34M derived: sum of 3 quarters · filed 2026-08-11 | -$4.34M 10-K · filed 2026-03-27 | |
| 2025-09-30 | -$1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.54M derived: sum of 2 quarters · filed 2026-08-11 | -$2.54M 10-Q · filed 2025-11-12 | $27.46M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$768.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$768.00K 10-Q · filed 2026-08-11 | $29.24M derived: sum of 3 quarters · filed 2026-08-11 | $29.42M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $30.01M derived: sum of 2 quarters · filed 2026-05-14 | $30.19M derived: sum of 3 quarters · filed 2026-05-14 | $28.11M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $30.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $30.19M derived: sum of 2 quarters · filed 2026-03-27 | $28.11M derived: sum of 3 quarters · filed 2026-03-27 | $589.55M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $185.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.89M derived: sum of 2 quarters · filed 2025-11-12 | $559.55M 10-Q · filed 2025-11-12 | $559.57M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $559.36M 10-Q · filed 2025-08-12 | $559.38M derived: sum of 3 quarters · filed 2025-08-12 | $559.39M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $561.44M 10-Q · filed 2025-05-08 | $561.46M derived: sum of 2 quarters · filed 2025-05-08 | $561.47M derived: sum of 3 quarters · filed 2025-05-08 | $561.25M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $27.00K derived: sum of 2 quarters · filed 2025-03-20 | -$192.00K derived: sum of 3 quarters · filed 2025-03-20 | -$883.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$215.00K derived: sum of 2 quarters · filed 2024-11-12 | -$906.00K 10-Q · filed 2024-11-12 | $222.60M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$219.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$910.00K 10-Q · filed 2024-08-08 | $222.60M derived: sum of 3 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$691.00K 10-Q · filed 2024-05-17 | $222.82M derived: sum of 2 quarters · filed 2024-05-17 | |||
| 2022-12-31 | $223.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $223.61M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $101.00K 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $284.06M 10-K · filed 2024-03-21 | ||||
| 2021-03-31 | $123.32M 6-K · filed 2021-05-06 | $123.72M derived: sum of 2 quarters · filed 2023-03-07 | $123.73M derived: sum of 3 quarters · filed 2023-03-07 | $123.43M derived: sum of 4 quarters · filed 2023-03-07 | |
| 2020-12-31 | $392.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-07 | $402.00K derived: sum of 2 quarters · filed 2023-03-07 | $105.00K derived: sum of 3 quarters · filed 2023-03-07 | $74.42M 20-F · filed 2023-03-07 | |
| 2020-09-30 | $10.00K derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | -$287.00K derived: sum of 2 quarters · filed 2020-11-05 | $74.02M 6-K · filed 2020-11-05 | $74.06M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-06-30 | -$297.00K derived: 6-K 6 month − 6-K 3 month · filed 2020-08-06 | $74.01M 6-K · filed 2020-08-06 | $74.05M derived: sum of 3 quarters · filed 2022-03-10 | $73.47M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-03-31 | $74.31M 6-K · filed 2021-05-06 | $74.34M derived: sum of 2 quarters · filed 2022-03-10 | $73.77M derived: sum of 3 quarters · filed 2022-03-10 | $183.17M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2019-12-31 | $34.00K derived: 20-F 12 month − 6-K 9 month · filed 2022-03-10 | -$542.00K derived: sum of 2 quarters · filed 2022-03-10 | $108.86M derived: sum of 3 quarters · filed 2022-03-10 | $108.86M 20-F · filed 2022-03-10 | |
| 2019-09-30 | -$576.00K derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | $108.83M derived: sum of 2 quarters · filed 2020-11-05 | $108.83M 6-K · filed 2020-11-05 | $108.83M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-06-30 | $109.40M derived: 6-K 6 month − 6-K 3 month · filed 2020-08-06 | $109.41M 6-K · filed 2020-08-06 | $109.41M derived: sum of 3 quarters · filed 2021-03-04 | $106.66M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-03-31 | $4.00K 6-K · filed 2020-05-07 | $4.00K derived: sum of 2 quarters · filed 2021-03-04 | -$2.74M derived: sum of 3 quarters · filed 2021-03-04 | ||
| 2018-12-31 | $0.00 20-F · filed 2021-03-04 | -$2.75M derived: sum of 2 quarters · filed 2021-03-04 | |||
| 2018-09-30 | -$2.75M derived: 20-F 9 month − 6-K 6 month · filed 2021-03-04 | $156.92M 20-F · filed 2021-03-04 | $156.49M 6-K · filed 2019-11-07 | $156.92M 20-F · filed 2020-03-03 | |
| 2018-06-30 | $159.66M 6-K · filed 2019-08-08 | ||||
| 2017-12-31 | $433.00K 20-F · filed 2019-02-25 | ||||
| 2017-09-30 | $127.69M 20-F · filed 2020-03-03 | ||||
| 2016-09-30 | $32.22M 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |